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Serialisation technology was introduced to protect the pharmaceutical supply chain from 
infiltration by falsified and substandard medicines. The implementation of serialisation 
systems required a substantial investment by pharmaceutical manufacturers. This study 
investigated the impact of serialisation on the operational efficiency and productivity in Irish 
pharmaceutical sites. Ireland plays an important role in the global pharmaceutical 
manufacturing network. All of the top ten largest pharmaceutical companies have 
manufacturing operations in Ireland. A review of the literature showed only limited 
publications on the topic of serialisation, operational efficiency, and productivity, particularly 
in the Irish context. A research method was designed to assess the relationship between 
serialisation, operational efficiency, and productivity. The research consisted of a survey and 
interview process with 11 manufacturing sites in Ireland. Participating companies operated a 
total of  114 pack-lines, representing  approximately 65% of the automated packing lines in 
the country. The research focused on measurements such operational equipment 
effectiveness (OEE), line availability, unit cost and cost per pack. The study revealed that 
serialisation had a negative impact on pack line OEE and line availability. The research found 
that serialisation had a negative impact on the unit cost of packaged pharmaceuticals. The 
study assessed the expected costs of serialisation with the actual costs experienced by 
manufacturers. The research found that the actual capital costs of serialisation were four 
times greater than the costs originally outlined by policymakers. The study identified a trend 
where Irish pharmaceutical sites are moving away smaller batch production and moving 
toward larger batches so as to gain greater efficiencies, The research also proposed the use 
of a serialisation depreciation factor ( 𝑆𝐷𝑓) as a method to determine the impact of 
serialisation on the cost of goods sold.   
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Since the 1980s the World Health Organization (WHO) identified a growing threat to patient 
safety from falsified and substandard medicines. These fake medicines had started to gain a 
foothold in the legitimate supply chain. There were multiple incidents where unsuspecting 
patients were given unsafe medicines resulting in injury and death. By the late 1990s the 
reported incidents of falsified medicines started to rise dramatically. Regulatory authorities 
started to take action to protect patients. Governments realised the strategic importance of 
the pharmaceutical industry and the scale of the threat posed by illegal medicines. 
Governments and regulators worked together to implement legislation designed to protect 
the legitimate pharmaceutical sales channels. The pharmaceutical industry also realised the 
danger posed by criminals operating in their industry. The risk to patient safety, reputational 
damage and the loss of revenue focused the pharmaceutical industry’s attention on 
counterfeit medicines.  
The introduction of anti-counterfeiting regulations has required a large investment by the 
pharmaceutical industry in new equipment and resources. The regulations introduced to 
protect pharmaceutical supply chains use serialisation technology to print a unique identifier 
on each pack of medicine. Every carton, bottle or vial of medicine produced for the U.S. and 
European markets must carry a serialised code that is unique to that pack. The serial code, 
expiry date and batch number are contained in a 2D matrix code mandated in regulations. 
See Figure 1. Serial codes are decommissioned at the point of dispensing by a pharmacist.  
 
Figure 1 An example of a 2D Matrix Code (GS1 Ireland and Enterprise System Partners, 2016) 
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To print and check a 2D Matrix code is simple. To flawlessly print 200 codes per minute on a 
24/7 cycle shift requires a great deal of skill and resources. Unit level serialisation creates a 
large amount of data that must be stored, retrieved, and communicated across multiple 
systems. A large pharmaceutical company will produce 650 GB of serialisation data annually 
(Willis, 2017). Any mismanagement of this data can lead to production line stoppages, 
product recalls and a halt to the supply of essential medicines to patients.  
The purpose of this research is to assess the impact of serialisation on the efficiency and 
productivity of Irish pharmaceutical sites. The first objective of this research was to determine 
if the assumptions and predictions outlined in the literature regarding the impact of 
serialisation on production efficiency were correct. With the benefit of hindsight and given 
the data now available the research sought to find if policy makers and industry 
representatives fully appreciated the impacts of serialisation at the factory floor level.  
The next objective was to quantify the impact of serialisation on operational efficiency using 
measurements such as Operational Equipment Effectiveness (OEE) and production line 
availability measures. Serialisation inherently requires the addition of new process steps into 
existing operations. The addition of new processes might infer a reduction in OEE. Conversely 
the addition of new equipment might increase OEE levels. The research looked at the 
literature to gain insight into the experiences of manufacturers in the post serialisation era. A 
research methodology was designed to assess Irish manufacturers experience with 
serialisation and OEE.  
The last objective was to determine if serialisation processes had an impact on site 
productivity. Serialisation required a substantial investment by the pharmaceutical industry 
in terms of capital expenditure. New expertise and resources were required to manage and 
operate serialisation system and to store and distribute data. Did this expenditure impact the 
cost of goods sold (COGS)? Did serialisation track and trace systems bring greater productivity 
by providing manufacturers with better data to manage supply chains? Productivity changes 
were measured using changes to the cost of goods sold (COGS) and unit pricing. The research 
also examined if the phenomena of serialisation and the trend toward operational excellence 
techniques coincided with each other to create a greater impact on productivity. If a trend 
toward smaller batch sizes coincided with the implementation of serialisation processes could 
these two changes in production process have exacerbated each other?  
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To determine what information was currently available to inform the research objectives a 
literature review was conducted. The purpose of the literature review was to: 
(i)  identify what consideration was given by policy makers and industry bodies as to 
the impact of serialisation on operational efficiency in the pre-serialisation phase 
and in the period after the implementation of serialisation processes 
 
(ii) Identify from the literature what information was available on the impact of 
serialisation on operational efficiency and to identify gaps in the literature that 
could be used to create a research model that could add to knowledge of the 
subject 
 
(iii) Identify from the literature what information was available on the impact of 
serialisation on pharmaceutical site productivity. To identify gaps in the literature 
that could be used to create a research model that could add to knowledge of the 
subject 
Following a review of the literature a research methodology was designed that sought data 
and input from Irish pharmaceutical manufacturing sites. The survey and interview process 
was broken into three sections. The first section was designed to understand the participants 
background and to determine the serialisation resources available at the company. This 
section sought to contrast the site’s actual serialisation experience with assertions found in 
the literature review.  
The second section of the semi structured interview process examined the impact of 
serialisation on operational efficiency by discussing OEE measurements and line availability 
measurements. Participants were shown part of a 2018 article published in the ISPE magazine 
where the impact of serialisation on OEE was discussed. Participants were asked to share their 
experiences of serialisation and OEE measurements. Respondents were also asked to 
comment on pack line availability.  
The final part of the assessment dealt with the serialisation and productivity. Participants 
were asked about the impact of serialisation on the Cost of Goods Sold (COGS). The final 
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section of the survey and interview also examined the relationship between average batch 
size, serialisation, and productivity.  
Data from the research was collated and the experience of different manufacturing sites was 
examined to create a series of findings. The findings drew upon the research survey data as 
well as input from interviews conducted with subject matter experts. The findings from the 

























7. Literature Review 
 
The literature review supported the main aim of the research to determine the impact of 
serialisation on operational efficiency and productivity on Irish pharmaceutical sites. The 
literature review sought to identify relevant journal articles, industry reports and other 
sources that could inform the key objectives of the research. Gaps identified in the literature 
were used to inform the methodology for the research.  The literature review was conducted 
in three phases. The first phase of the literature review examined on how and why policies 
were developed to tackle counterfeit medicines. This section also examined the scale of the 
falsified medicines issue and how serialisation technology was chosen as the tool to protect 
the legitimate pharmaceutical supply chain. This section of the literature review also 
examined how policy makers and industry stakeholders considered  the impact of serialisation 
processes on operational efficiency and productivity. Did policy makers and industry bodies 
consider efficiency and productivity during the formulation of serialisation regulations and its 
impact in the post serialisation period?  
The next phase of the literature review examined the available literature on how operational 
efficiency is measured in the pharmaceutical industry. A search was conducted to find articles 
on how the pharmaceutical industry adopted serialisation technology and if serialisation 
systems had hindered or helped efficiency. This section also sought contributions about line 
availability.  
The final section of the literature review focused on productivity. The review examined how 
productivity is measured in the pharmaceutical industry. Contributions on the cost of goods 
sold and unit cost were examined. The literature review sought to examine articles on the 







Literature Review Strategy 
Phase Topic Sources 
Phase I Development of serialisation policies and the 
considerations given to efficiency and productivity 
in policy development 
E.C. Reports, Interpol, EUIPO 
Reports, ASOP, WHO, FDA, U.S. 
Congress 
Phase II Measurement of operational efficiency in the 
pharmaceutical industry and the impact of 
serialisation 
E.C. Reports, FDA Reports, 
Industry journal articles and 
industry magazines,  
Phase III Measurement of productivity in the 
pharmaceutical industry and the impact of 
serialisation on productivity in pharmaceutical 
packaging companies 
E.C. Reports, FDA Reports, 
Industry journal articles and 
industry magazines, 
Table 1 Literature review strategy 
Search tools used in the literature review included Sage Journals, EBSCO, Google Scholar, 
ResearchGate, PubMed, EOLAS, Emerald Insight and J-Stor. The literature review used a 
combination of Boolean Search functions which included both the UK spelling of 
“serialisation” and the U.S. spelling “serialization”. Variations of “operational effiectiveness”, 
“OEE”, “Operational Excellence”, “OPEX” and “impact” were used in the Boolean searches.  
 
7.1 Ireland’s role in combatting counterfeit medicines 
Ireland plays an important role in the fight against counterfeit medicines. Irish based 
pharmaceutical companies must meet the regulatory demands of all the markets supplied 
from Ireland. Leading pharmaceutical companies such as Johnson & Johnson, MSD, Amgen, 
Pfizer, Gilead, Abbvie and Sanofi have manufacturing operations in Ireland. (IDA, 2020). All 
ten of the global top ten pharmaceutical companies have manufacturing operations in 
Ireland. The value of pharmaceutical exports from Ireland in 2018 was €73bn. (IBEC, 2019). 
Irish based pharmaceutical companies produce active pharmaceutical ingredients (API) and 
bulk biologic medicines as the raw material for other global pharmaceutical sites. Semi-
finished vials and fully packaged medicines are also supplied for global markets. The Irish 
regulator, HPRA (Health Products Regulatory Authority) oversees pharmaceutical 
manufacturing activities in Ireland. Irish based manufacturers must meet the good 
manufacturing practise (GMP) and quality management standards of all the markets served 
including the U.S. Food and drug Administration (FDA). The majority of Ireland’s 2019 exports 
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(€39bn) going to the U.S. market are made up of pharmaceutical products.  (Gov.ie, 2019). 
While Irish based pharmaceutical companies will meet the regulatory demands of all the 
markets they supply, the EMA and FDA take a leading role in regulatory development and 
expectation.    
7.2 Scale of the trade in counterfeit medicines 
Estimations vary on the value of trade in counterfeit medicines. There is consensus that sub-
standard and falsified medicines present an enormous risk to patient safety and to the 
legitimate medicines supply chain.  One analysis by the Havoscope company, who specialise 
in black market research put the direct value of the counterfeit drugs trade at $200bn per 
annum (Havoscope, 2020). 
It can be difficult to assess the scale of the black market in counterfeit drugs. By its very nature 
the trade in illicit medicines is controlled by criminals and can be dangerous to investigate. 
Drug companies may be aware of copies of their medicines in some markets but may be slow 
to discuss these findings publicly. (Cockburn et al., 2005).  
The difficulty in compiling comprehensive data is particularly acute in developing countries. 
In an interview, Dr. Paul Newton Head of the Wellcome Trust Tropical medicines research 
program in Laos said that “the paucity of reliable data means that it is difficult to know 
whether the problem is getting better or worse, how the epidemiology of substandard and 
falsified medicines differ and whether interventions are effective” (Newton et al., 2001). 
 
7.3 Pharmaceutical supply chains complexity 
Pharmaceutical supply chains are complex and stretch across the globe. Pharmaceutical 
brands may decide to manufacture products at their own facilities, or they may decide to use 
a contract manufacturing organization (CMO). Raw materials may come from low cost 
economies such as China or India. Pharmaceutical brands may use contract partners to 
manufacture raw materials on their behalf. A pharmaceutical company may fill semi-finished 
product into primary packaging at their own facilities but may then have an outsourced 
contract packaging organization (CPO) manage the packing of drugs into labelled secondary 
packaging. Finished products may then go to an in-house distribution centre or may instead 
go to a licensed third-party logistics provider (3PL) or to  a licensed wholesaler/distributor. 
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The complexity of the pharmaceutical supply chain is highlighted in Figure 1, sourced from a 
WHO report on counterfeit medicines. (Pisani, 2017) 
 
Figure 2 Pharmaceutical Supply Chain Complexity. Source WHO Global Surveillance and Monitoring System for substandard 
and falsified medical products (Pisani, 2017) 
The complexity of the pharmaceutical supply chain makes it susceptible to infiltration both in 
terms of sub-standard raw materials and fake finished products. The adoption of serialisation 
systems is just one of the tools used to combat illegal medicine supply.  
7.4 Examples of falsified medicines in the supply chain 
Heparin is a blood thinning drug used to treat dialysis patients and seriously ill post-operative 
patients to prevent blood clotting. In 2008 fake versions of the Heparin started to appear in 
the U.S. market. The active pharmaceutical ingredient in Heparin was switched for a cheaper 
chemical compound with  anti-coagulant properties (Hubbard, 2009).  Infections caused by 
injections of the fake Heparin caused the death of  81 patients in the U.S. (Harris and 
Bogdanich, 2008). The contaminated Heparin caused a Serratia Marcescens bacterial 
infection.  In one outpatient treatment clinic in Texas the use of the fake Heparin caused 
infections in 67 patients, many of whom were recovering cancer patients. (Su et al., 2009). 
There were also reports of infections from the counterfeit Heparin in the EU, though 
thankfully these did not result in any deaths. (European Medicines Agency, 2018) 
 In 2012 reports emerged of counterfeit Avastin circulating in the U.S. market. Avastin 
(Bevacizumab) is a drug developed by Roche and Genentech as an oncology medicine for the 
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treatment of tumours. Avastin achieved sales of $6bn USD in 2012. The product cost about 
$2,500 per dose. The counterfeit medicine entered the U.S. market via an online website 
Canadadrugs.com. When U.S. regulators tested the fake Avastin they found it contained no 
active pharmaceutical ingredients. (Mackey et al., 2015) 
The Canadian distributor relabelled a Turkish market version of Avastin, branded Altuzan, 
from a UK wholesaler. The British wholesaler had purchased the counterfeit medicine from a 
Danish company who in turn had purchased the product from a Swiss dealer who sourced it 
from an Egyptian distributor via a Syrian dealer. The Avastin scandal is an excellent example 
of the complexity of the global pharmaceutical supply chain and the difficulties involved in 
protecting legitimate sales channels from unscrupulous agents. (IRACM and Przyswa, 2013) 
In another 2002 case, criminals in Florida relabelled 110,000 doses of the drug Epogen 
(AGOVINO, 2002). Epogen is used as a treatment for anaemia and is used as a drug therapy 
in chemotherapy and late stage kidney failure. Patients reported, painful adverse reactions to 
the fake Epogen. By relabelling vials with a lower concentration of the drug as having a higher 
strength the criminals netted a $46m USD profit. (PEW Health Group, 2013) Only 10% of the 
counterfeit drugs put into circulation by the criminal gang were ever recovered. (Thompson, 
2003) 
Data from the seizure of illicit medicines data can provide some insight into the scale of the 
counterfeit medicines threat. Each year a report is compiled detailing customs activities 
across all the EU member states. Only a small percentage of counterfeit drugs coming from 
outside the customs union ever get caught by customs officials. However, the customs union 
wide report presents an overall picture of the situation for falsified medicines and can help 
determine some of the scale of the challenge. In 2007 over 4 million articles of counterfeit 
medicines were seized by customs officials (European Commission, 2008). By 2011, this 
number had increased over 5-fold to 27.4m articles of medicine with a retail value of €27.6m 
(European Commission, 2012). We can see that at the time of policy formation regrading 
falsified medicines and serialisation that the threat of unlicensed drugs was growing at an 
alarming rate. Even allowing for growth in EU membership and more effective action from 
customs officers the trend was certainly going in the wrong direction. By 2013, prior to the 
introduction of serialisation controls, the situation had started to reverse. 2013 numbers were 
half that of 2011 with 3.6m articles seized to a retail value of  €11.9m (European Commission, 
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2014). By 2017, the situation showed even greater improvements with only 0.5m items seized 
with a retail value of €6.9m (European Commission, 2017a). Numbers from the latest 2018 
report are even lower again with 166,000 articles seized with a retail value of just over €4m 
(European Commission, 2019). So, from an EU internal market perspective the threat from 
unlicensed medicines has subsided for the moment or counterfeiters have found a very novel 
way round customs controls.  
International police operations can also provide insight into activities of organised criminal 
gangs in the unlicensed medicines black market. The annual EUROPOL MISMED operation is 
a Europe wide crackdown on the illegal trade of falsified medicines. In 2020 the week long 
operation MISMED III operation led to the arrest of 165 individuals, the seizure of 36 million 
doses of medicine to a retail value of €7.9m. In three years EUROPOL’s MISMED program has 
led to the arrest of 600 suspects and the seizure of €0.5bn of counterfeit medicines. (Europol, 
2020) A wider international net is spread through the global INTERPOL police network. 
Operation Pangea has been running since 2008 and has led to the seizure of  more than 105 
million units of medicine and the arrest of 3,000 suspects.  
As a super-national entity, the EU has a commitment to protecting its external borders while 
at the same time promoting the free movement of goods and intra-national trade within the 
community. Medicines are often legally, relabelled for sale in different member state 
markets. For example, a product that was originally labelled for the German market can be 
legally re-labelled under license for sales in another market. Parallel market relabelling 
operation may also take medicines from outside the EU for remarketing in another EU 
member State. While this free movement of goods is accepted the activity is seen as 
susceptible to infiltration or abuse by criminals. The European falsified medicines directive 
demand specific measures, including serialisation, to control parallel trade.  In the U.S. parallel 
trade is also treated as a susceptible point of entry for illegal medicines into the supply chain. 
(Liang, 2006) 
Another phenomenon in the trade of falsified medicines, involving customs controls, is the 
trend towards using methods of trans-shipments and free ports. This is where unlicensed 
medicines are imported from a country with high standards of compliance before being 
routed to their final market. For example, a batch of counterfeit medicines manufactured in 
Pakistan, bound for the market in Ireland, might first be routed through a shell company and 
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a port in the U.S. of Japan. Customs authorities in Ireland would be less suspecting of material 
coming from these destinations than other higher risk countries. This method helps criminals 
get around the risk assessment procedures of local customs agencies. (European Commission, 
2005) 
The European Union Intellectual Property Organisation (EUIPO) has worked with the 
Organization for Economic Cooperation and Development (OECD) to offer a deep analysis of 
the impact of counterfeit medicines in the European Union. In a 2020 report the EUIPO and 
OECD use a figure of €4.4bn for the global trade in counterfeit medicines. The report outlines 
that 38% of seized counterfeit medicines infringe U.S. patent and trademark rights. European 
trademark and patent holders are the next most effected group (EUIPO and OECD, 2020) 
Another 2019 EUIPO report estimates the indirect impact of counterfeit medicines on the 
European pharmaceutical industry. The report calculates that unlicensed medicines cost 
37,700 jobs in the EU. Another 53,000 jobs are lost in supporting activities. The statement 
sizes the cost of counterfeit medicines at €10.2bn per annum when lost revenue is taken into 
account (EUIPO and OECD, 2019) 
Along with financial cost the EUIPO/OECD report also highlights the human cost of fake 
medicines. Between 72,000 and 169,000 children die annually from pneumonia having taken 
substandard antibiotics.  The report cites Singapore, Hong Kong and Singapore as major hubs 
for fake drugs. This is validated by the EU customs seizures reports previously discussed. The 
unscrupulousness of the criminals that falsify life-saving medicines was already highlighted 
by WHO reports. The EUIPO/OECD report gives more detail on the types of medicines that 




Figure 3. Most Counterfeit medicines (Pharmaceutical Security Institute, 2020) 
The EUIPO report references the work of the Pharmaceutical Security Institute (PSI). The PSI 
gathers incident data privately from pharmaceutical companies. Pharmaceutical companies 
may become aware that their products have been counterfeited but may not wish to 
publicly highlight these incidents. The PSI gathers information directly from pharma 
companies where product has been stolen, illegally diverted, or discovered to be 
counterfeit. PSI reporting highlights that incidents of product falsification continue to grow 
at a pace. The PSI reported 5,081 pharmaceutical crime incidents in 2019. This was up 15% 
on 2018 and is a 69% increase on 2014 figures. These numbers are in contract to the trend 
in the European Union, as outlined in the annual EU customs seizure reports.  The PSI 
number refer to global incidents  
 




The CMPI report, discussed previously is also referenced in a report from ASOP – The Alliance 
for Safe Online Pharmacy (ASOP, 2017)  The availability of counterfeit medicines for sale via 
the internet is referenced as a major concern for governments and regulators.  The 2017 ASOP 
report makes a number of assessments on the scale of the counterfeit drug market in Europe. 
Based on extrapolations from INTERPOL drug seizures during their operation Pangea, ASOP 
calculated the value of the counterfeit medicines market in Europe was estimated at €365m 
per annum. This estimate only considers the retail value of the drugs themselves. Other 
factors should also be taken into account. For example, the loss of revenues and reputational 
damage to pharma companies, lost taxes to Governments and untreated health costs. Taking 
these costs into account,  ASOP estimates the cost of the online trade in online fake medicines  
to the European Union member states at between €935m - €3bn per annum.  
The European Union must balance the risk posed by illicit online pharmacies with the EU’s 
commitment to open trade and reducing costs to patients and citizens.  
The ASOP report refers to a Legiscript survey of the number of illegal websites shutdown in 
Europe between 2010 and 2012 following EUROPOL operations 
 
 
Figure 5  Operation Pangea – Websites shutdown (ASOP, 2017) 
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The ASOP report highlights an interesting case between Google and the U.S. Dept. of Justice. 
Google forfeited $500m in a settlement because of revenues from the promotion of illegal 
online pharmacies in the U.S. dating back to just 2008. The ASOP report point out that if a 
network of online pharmacies was paying hundreds of millions of dollars in online promotion 
then this must certainly be a lucrative market.  (U.S. Dept of Justice, 2011) 
7.6 The impact of falsified and sub-standard medicines on the developing World 
When we consider the real damage caused by falsified medicines in the well-regulated and 
technically advanced Western World, we can imagine the impact these counterfeit products 
can cause in the developing world. The World Health Organization (WHO) and the World 
Health Assembly (WHA) recognised the growing threat of counterfeit medicines as far back 
as 1988. (World Health Assembly, 1988). The WHO started to publish warnings about 
counterfeit medicines and attempted to raise awareness of the issue. WHO factsheet No. 275 
indicated 10% of medicines in the developing World were substandard or falsified. (WHO, 
2003).  
The WHO Factsheet offered evidence of the devastating effects of counterfeit medicines in 
developing countries. One case involved a breakout of meningitis in Nigeria in 1995. Médecins 
San Frontier staff noticed that vaccine medicines were difficult to reconstitute and contained 
foreign particles. After contacting the vaccine manufactures it was confirmed that the 
vaccines were counterfeit. 2,500 people died because of these fake drugs (Pécoul et al., 1999)  
Another case mentioned in the WHO factsheet relates to an investigation into critical anti-
malarial drugs in South East Asia. Nearly 40% of drugs purchased from stores contained no 
active ingredient. (Newton et al., 2001). While counterfeit medicines represented far less 
than 1% of the market in wealthy countries, these drugs were primarily used for lifestyle 
applications (hormones, steroids, antihistamines). In the developing World, counterfeit 
medicines are often unwittingly purchased to treat life threatening diseases such as HIV, 
Malaria and bacterial infections.  
In 2011, more than 200 patients died after they were given counterfeit heart medication in 
Lahore, Pakistan. Over 1,000 people became seriously ill because of the treatment. Symptoms 
included bleeding from the mouth and gastrointestinal tract, dark marks ion the patients’ skin 
and very low levels of white blood cells. (WHO, 2013) 
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7.7  Technology choices and patent trolls 
 
In the period 2000 to 2005, the FDA seemed to favour Radio Frequency Identification (RFID) 
as a probable technology to offer a track and trace solution to protect the legitimate 
medicines supply chain (Ault, 2004). RFID Ultra High Frequency (UHF) is a passive micro circuit 
that can be stimulated to provide information when scanned. A number of drug companies 
ran trials using RFID tags on pharmaceutical packaging. Pfizer trialled RFID tags on its Viagra 
medicines and reported positive results (Thomas, 2006b). Glaxo SmithKline also 
experimented with RFID technology (Thomas, 2006a). In 2006, Congressman Dan Burton 
proposed the “Reducing Fraudulent and Imitation Drugs Act of 2006”. This Act would have 
stipulated the use of RFID technology on pharmaceutical packaging (Burton, 2006). The bill 
did not make it through the legislative agenda of the 109th Congress. The WHO also 
referenced RFID technology as a technical solution to counteract falsified medicines (WHO, 
2007). The European Medicines Agency also investigated the use of RFID technology. By 2011, 
the European Commission had already issued a directive that a system would be developed 
to uniquely identify each pack of medicine manufactured and dispensed. At that point 
however the European Commission had not yet stipulated the exact mechanism for track and 
trace technology. Three types of technology were considered; RFID, Linear barcode and 2D 
barcodes (Irish Medicines Board, 2011). The European Commission started a consultation 
process with industry stakeholders to assess the merits of the technology options (European 
Commission HEALTH AND CONSUMERS DIRECTORATE-GENERAL, 2011).  
A pharmaceutical track and trace system must hold a lot of data on the drug label: country of 
origin ID, Manufacturers ID, National Drug Code, Product type, a serial number, lot number 
and expiry date. Hence the references to the use of RFID technology in the literature from 
2000 to 2007. There was however another type of data capture technology called the 2D data 
matrix code. The 2D Data Matrix code mentioned in the 2010 FDA guidance is a type of printed 
code that can hold up to 2335 alpha numerical characters. The 2D data matrix code was 
invented in 1953 by Jerome Lemelson. As a data carrying technology the 2D data matrix code 
was very suitable for serialisation. The 2D matrix code could carry a large amount of alpha-
numeric data, it was cost effective and compatible with existing print and bar code reading 
systems. However, the technology was subject to patent protection and the Lemelson 
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foundation was actively enforcing patent rights and collecting hundreds of millions of dollars 
in licensing fees from large corporations for the use of the technology. Given the commercial 
nature of the technology regulators could not recommend the 2D Matrix labelling method in 
the early 2000s (Hansen, 2004).  
In 1999 the machine vision companies Cognex and Symbol sued the Lemelson foundation and 
in 2004 won their legal battle. This opened the use of 2D Data matrix technology for industrial 
track and trace processes including the pharmaceutical industry. In 2006 the International 
Standards Organization (ISO) published ISO16022 as the international standard for the use of 
2D datamatrix codes (ISO, 2006, p.16). The ISO also published a standard on how to grade the 
print quality of 2D Data matrix codes (ISO, 2004, p.15)  
The availability of 2D data matrix codes was quickly embraced by the pharmaceutical industry. 
In 2007 the French pharmaceutical regulator AFSSAPS (Agence française de sécurité sanitaire 
des produits de santé) launched a program to replace pharma barcodes with 2D data matrix 
codes, as a traceability and verification system (Club Inter Pharmatique, 2007). 
 
7.8  International standardisation and serialisation 
 
By the mid 2000’s both the FDA and the EMA recognised the need to take action to counteract 
the threat posed by unlicensed medicines. Regulatory authorities recognised the growth in 
the sale of unlicensed and substandard medicines on the internet, the infiltration of fake 
drugs into legitimate pharmaceutical supply chains and the reputational damage caused by 
dangerous counterfeit medicines in developing countries. In 2003, the then FDA Director 
Mark McLellan launched a counterfeit medicines task force to come up with new ways to 
thwart criminal activity in illegal medicines. (outsourcing-pharma.com, 2003) Part of the remit 
of the taskforce was to identify new technologies that could be used in the fight against illegal 
medicines. An interim report was published in 2004 that detailed the Task Force’s 
consultation process with manufacturers, wholesalers, pharmacists, medical practitioners, 
and technology providers. The report detailed how the task force had held a series of public 
meetings. There were 72 presentations made at these meetings and 54 exhibits from various 
technology providers (FDA, 2004).  
26 
The European Commission adopted a very similar approach to their counterparts in the U.S. 
on the development of a technology response to the threat of counterfeit medicines. Like the 
FDA the European Commission sought a response to various policy options from industry 
stakeholders(European Commission HEALTH AND CONSUMERS DIRECTORATE-GENERAL, 
2011) . The responses from the industry were then collated in an impact assessment report.  
There were important responses from industry stakeholders in Europe to the European 
Commission’s request for submissions. The European Federation of Pharmaceutical Industry 
Associations EFPIA submitted a response that supported the use of 2D data matrix codes 
(EFPIA, 2012). The EFPIA also submitted a joint paper with GS1 outlining a common approach 
to using GS1 standards, in particular the GTIN number, in the European Falsified Medicines 
framework (EFPIA and GS1 AISBL, 2012).  The EFPIA had originally endorsed the use of a 2D 
Matrix based tracking system in 2006 (European Medicines Verification and System (EMVS) 
Alliance, 2017).  The EFPIA was also involved in another submission to the European 
Commission as part of a consortium along with the IFPMA (International Federation of 
Pharmaceutical Manufacturing Associations) and the PhRMA (Pharmaceutical Research 
based Manufacturing Association) (IFPMA et al., 2013). The consortium report again 
highlighted the need for the European falsified medicine policy to be based on international 
standards, citing GS1’s data matrix code as a preferred standard for track and trace coding.  
The report also highlighted expected regulation in Belgium, California, Brazil, China, India and 
other countries. The IFPMA, EFPIA and PhRMA submission highlighted the hardware and 
software costs of serialisation. They urged the European Commission to adopt an approach 
based on international standards that would allow manufacturers to use their investment in 
serialisation not just for the European market but for other international markets as well. 
There were also submissions from the European Hospital Pharmacists Association (EAHP) 
which again urged the European Commission to adopt international standards based on GS1 
coding standards (EAHP, 2020).   
In another stakeholder submission, the European Consumer Organisation (BEUC) also 
supported the use of the 2D matrix codes. The BEUC considered that the use of 2D Matrix 
codes would have the least impact on the eventual cost to the consumer. The BEUC also 
supported a harmonised regulatory approach across all member states in order to minimise 
the cost to manufacturers and therefore to any onward cost to consumers (BEUC, 2012).    
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During the period of policy development, it was clear that both the U.S. and European 
regulators were actively watching each other’s progress to align as closely as possible in terms 
of anti-counterfeiting mechanisms. Both regulators looked to the GS1 standards organisation 
when shaping guidance and legislation. GS1 is a not for profit organisation that develops and 
coordinates barcoding standards. GS1 operates in 112 countries, it has 1.5 million member 
companies its barcodes and other data recording methods are used in over 6 billion 
transactions daily (GS1 Ireland, 2019, p.1).  The FDA guidance document refers to the 
importance of international standardisation in the formation of track and trace systems. The 
FDA ensured that the SNI system was compatible with the GS1 Standards. While the FDA 
guidance did not obligate manufacturers to use the format laid out in GS1 standards the 
format suggested by the FDA was compatible with the GS1 organization. The Healthcare User 
Group (HUG) also started to focus on the use of data matrix codes (GS1 AISBL, 2007). The GS1 
was uniquely positioned to garner interest from manufacturers, logistics providers, retail 
pharmacists and regulators on the use of 2D data matrix codes to track and trace drug 
products. GS1 also operated globally and could ensure good communication on standards 
between stakeholders. GS1 highlighted the small print size of 2D data matrix codes as a 
distinct advantage for the technology (GS1 AISBL, 2013, p.1) 
In addition to standardised 2D data matrix codes, GS1 also offered a standard for 
synchronising data exchanges; Global Data Sharing Network (GDSN). This standard would 
become important as a guide to the development of data exchanges mechanisms for 
serialised codes on drug packages. A 2012 McKinsey report on the use of standardised 
tracking systems, including GS1’s GDSN exchange pointed to a healthcare supply chain that 
connected patients, healthcare workers, medicines and medical devices in a seamless 
continuum of data (Ebel et al., 2012). In reality, regulators tried to provide for as much 





7.9 The expected costs of serialisation 
The EFPIA response to European Commission on the Falsified Medicine Directive included an 
estimation on the expected costs of implementation for manufacturers. The EFPIA report 
referenced a total annual cost to the pharmaceutical industry of €125m for serialisation. This 
cost included all aspects of the pharmaceutical supply chain from manufacturing, to 
distribution and dispensing. No detail is provided on this cost in the submission. The EFPIA 
report also cites a cost of 1.6 cent per pack of medicine and an annual cost to a large 
manufacturer of €8m per annum. In its submission the EFPIA stated that an average 
manufacturer would have €7bn in sales and produce 500m packs of medicine per year (EFPIA, 
2012).  
The European Commission published the correspondence from industry associations, 
pharmacist representative bodies, health insurers, wholesalers and manufacturers. In total 
there were 100 stakeholder responses from industry. While some of the submissions from 
industry stakeholders, such as the submissions from Pfizer and Amgen refer to the cost of 
serialisation none mention an impact on the operational efficiency of manufacturing sites.  
Of the 100 submissions to the European Commission in the consultation process no  
consideration was given to a potential impact on manufacturing efficiency and therefore a 
potential impact on the availability of medicines (EUROPEAN COMMISSION Enterprise + 
Industry, 2008).  
In the final European Commission’s impact report on the falsified medicines directive there is 
also no reference to any possible impact on operational efficiencies. The report does give 
detail on operational costs. The report estimates that once off costs for serialisation 
technology would come to €150,000 per pack lines. Across the 12,000 non-prescription 
medicines pack lines this would mean an industry investment of €1.8bn for line upgrades. In 
addition, another €4bn investment was required to provide the necessary IT systems to 
manage the flow of serialised data. The final report estimated that printing and packing of 
serialised codes would cost 2 cent per pack in the first five years. Falling to a half a cent per 
pack after 5 years, presumably due the depreciation of equipment. These costs are based on 
the cost of consumable materials and labour. There is no consideration of the impact on 
productivity. With 14.85bn packs of prescription medicines traded annually in the EU, 2 cents 
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per pack equates to an industry cost of €297m per annum just to print and check serialisation 
codes on European pack lines (COMMISSION OF THE EUROPEAN COMMUNITIES, 2008b). 
In the U.S. the FDA did not directly carry out a similar impact report, however there were a 
number of indirect reports that did assess the potential impacts of serialisation processes on 
the industry. The Pew Healthcare foundation published comprehensive research from 
Forrester Research that estimated the costs associated with serialisation. The Pew Healthcare 
report, based on estimates from both pharma companies and vendors, set the average cost 
to serialise a pack line at $1.4m. This cost includes not just the cost of equipment and software 
but also the cost to implement the project and enterprise costs. This cost was a multiple of 
the European Commission’s estimates. The report does highlight additional labour costs of 
$291,000 per annum, per pack line. There is no reference to an impact on operational 
efficiency in the report (Pew Foundation and Booz Allen Hamilton, 2014). The report stated 
that there was no public analysis available on the costs associated with the implementation 
of serialisation at the time of publication.  
The U.S. Center for Disease Control (CDC) did publish an impact assessment report on 2D data 
matrix code printing on the vaccines supply chain. The report considered the impact of 
serialisation on manufacturers, distributors and healthcare providers (Robinson et al., 2013). 
The report cited the complexity of printing 2D matrix codes compared to traditional linear 
barcodes. Regulations stipulated that manufacturers achieve a minimum ISO grade C for 
printed labels. Each label must be checked to ensure its readability. Barcode scanners are too 
slow to read all the labels on a high-speed pack line and therefore industrial grade cameras 
are used. Along with the complexity of the 2D codes, the FDA stipulated that manufacturers 
would still be expected to print linear barcodes on packaging, thus increasing the risk of 
printing errors (Center for Drug Evaluation and Research, 2018). Again, the CDC impact report 






7.10 Manufacturing Efficiency 
 
In manufacturing environments operational efficiency is often measured using the OEE 
method (Overall equipment Effectiveness). The OEE concept was first introduced by Seiichi 
Nakajima in the seminal work, Total Productive Maintenance (TPM) published in 1988 
(Nakajima, 1988). Nakajima identified six factors that had the most impact on OEE. These are 
known as the big losses.  
(i) Equipment failure/breakdown losses 
(ii) Setup/adjustment time 
(iii) Idling and minor stop losses  
(iv) Reduced line speed 
(v) Reduced yield until machines stabilise 
(vi) Quality  
 
 The OEE calculation provides a common standard to determine  production efficiency in 
different manufacturing sites and industrial sectors (de Ron and Rooda, 2006). OEE is made 
up of three elements (i) Performance, (ii) availability (iii) quality. Performance is a 
measurement of line speed. A packaging machine rated to produce  200 packs per minute but 
that only produces 100 packs is operating at 50% performance. Availability is a measure of 
time. The percentage of stoppage time during which a pack line should be available for 
packing processes. Quality is the measurement of the percentage of good quality products 
produced from the total. The OEE is calculated as a composite of all three measurements.  
OEE % = % Performance X % Availability X % Quality 
Serialisation has the potential to affect the three measures making up the OEE calculation. . 
We have already discussed the ISO standards that measure the quality of the 2D data matrix 
codes on the medicine pack (ISO, 2006). The requirement to print complex 2D matrix codes, 
apply tamper evidence seals and check the readability of print may slow the pack line speed 
performance. Line availability may be affected by the time it takes for operators to setup 
serialisation data, clear down unused serialised codes and by the stoppages caused by poor 
quality print.  
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While there was an absence of comments on pack line efficiency in the impact reports by the 
CDC and the European Commission, there was some industry realisation for the potential of 
a negative impact on OEE. Rotunna et al commented that “due to the highlighted changes on 
the process operations, there could be also an impact on the overall equipment effectiveness 
(OEE) of the production line. The continuous data exchange between different components, 
synchronization, and the necessity of waiting for data valid signals may result in overall line 
speed reduction, with a consequent loss in terms of performance efficiency” (Rotunno et al., 
2014). The Rotunna article did not quantify the impact on pack line efficiency. A 2017 report 
from Pharma Logistics IQ also cited efficiency related costs but these were also unquantified.   
The Serialization Playbook published by Healthcare Packaging magazine did estimate the 
negative OEE impact at between 8% to 10% post implementation. The playbook estimated 
that OEE would recover to a point 4% lower than pre serialisation (Rodgers, 2014). This range 
of OEE loss was validated in an article in Pharmaceutical Commerce magazine where a loss of 
between 5% and 10% was estimated for the period after ramp-up and stabilization. However, 
losses of up to 30% were observed during the ramp up period after implementation (Ozkaya 
et al., 2017). The article also made the point that operators would need training and 
experience so as to maximise efficiency post serialisation. The International Society of 
Pharmaceutical Engineers (ISPE) published an article on OEE losses due to serialisation 






Figure 6  (Penfold, 2018) 
 The ISPE article indicated losses of between 10% to 25% for up to 2 months post serialisation 
implementation. Lines may recover to a position 1% to 5% lower than the original OEE 
position after about six months (Penfold, 2018). In a discussion with the author of the article, 
Alfred Penfold, it was determined that these calculations were based on a combination of the 
Healthcare Packaging serialisation playbook (Rodgers, 2014), personal experience and input 
from industry colleagues. Due to the emerging nature of the technology there was not a large 
amount of supporting literature for the OEE impact claims in the ISPE article. The industry 
sources contributing to the ISPE article would have been close to global serialisation roll-out 
programs.  
One of the advantages of the 2D Matrix Codes (DMC) used for serialisation is that they are 
forgiving from an operational perspective. The DMC is readable from any orientation. The 
codes have built in error correction that allows a printed code with up to 30% degradation in 
print quality to still  be effectively read. From an OEE quality factor perspective the 2D data 




7.11 Planned downtime productivity and Equipment efficiency 
 
The Harvard Business Review defines productivity as “the number of labor hours required to 
accomplish a given task, when compared with the standard in that industry or setting.” A 
productivity gain is when a manufacturing site manages to produce more with the same 
resources, compared to peer companies i.e. doing more with the same resources. The same 
publication defines efficiency on the other hand as “doing the same with less. Companies 
most often improve labor efficiency by finding ways to reduce the number of labor hours 
required to produce the same level of output” (Mankins, 2017) So efficiency can be described 
as doing more output with less resources while productivity is doing more with the same 
resources. The serialisation implementation process is not a single event. Software and 
hardware need to evolve to meet regulatory and market requirements. As new regulations 
are released in different markets, manufacturers must adopt their serialisation systems to 
meet these market demands. Figure 11 outlines the release of track and trace regulations in 
different markets over the last decade. From figure 11 we can see that international 
regulations are constantly evolving. As regulations evolve so must the software and hardware 
on packaging lines.  
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Figure 7  (GS1 AIBL, 2016) 
 
Each time a serialisation system is updated to meet these regulatory requirements the 
packaging line must be stopped. These stoppages effect the productivity of the manufacturing 
site. Updates to serialisation equipment are classified as planned maintenance and do not 
affect the availability measures in OEE. Even though these stoppages are planned the effect 
on productivity should be measured. Reductions in productivity will be reflected in the cost 
of goods (COGS) from the site. Increases in the COGs are ultimately reflected in the price 







Along with productivity measurements Bragli et al have proposed a modification to the OEE 
calculation to account for the loss of availability due to planned maintenance events. The 
OEEM measurement uses the standard OEE measurement and multiples by a factor Apm, 
which is the loss of availability due to planned maintenance (Braglia et al., 2009).  
𝑂𝐸𝐸 = 0𝐸𝐸𝑀𝑥𝐴𝑝𝑚 
Another alternative measure to OEE is the Equipment Effectiveness rate (E) proposed by de 
Ron and Rooda (de Ron and Rooda, 2006). The equipment effectiveness E rate has three 
factors similar to OEE; Yield Y, Rate R and Availability A.  
Equipment Effectiveness E = A x R x Y 
The calculation of the Availability factor A is interesting in terms of the discussion on the 
impact of serialisation. In the original work by Seiichi Nakajima on Total Productive 
Maintenance (TPM) the availability factor was calculated by considering the time available 
per day less the planned down time. The OEE standard published by SEMI uses total available 
time i.e. 24 hrs per day for its availability measurement. De Groote defined available time as 
planned production time less unplanned downtime (De Groote, 1995).  
 









The SEMI standards on Reliability, Availability and Maintenance provide a comprehensive 
consideration of availability states in  a production environment. See Figure 9.  
 
Figure 9 (SEMI, 2012) 
 
De Ron and Rood further categorise the time given to different machine states. Availability 
factor A is calculated by breaking down the state of equipment into six categories: Non-
operational state, no-input state, no-output state, unscheduled downstate, scheduled 
downstate, productive state. This categorisation is based on the E10 standard for Reliability, 
Availability and Maintenance (RAM) published by the Semiconductor Equipment and 








The availability factor calculation for E focuses on the last three categories: unscheduled 
downstate, scheduled downstate, productive state. The availability factor A is a measure of 
the environment in which the machine operates. The first three categories of state (non-
operational, no-input, no-output) are not seen as being under the influence of machine 
operations. By focusing on those factors that relate directly to equipment the Equipment 
Efficiency factor E is a truer reflection on the equipment’s impact on productivity.   
 
Figure 10 (de Ron and Rooda, 2006) 
 
 
In the Rooda and de Ron model Availability factor A is calculated as the  follows. 
 
Where, Te is the Effective Time and T0 is the Productive time. 
As serialisation processes evolve with new regulatory demands how is the time required to 
update and maintain systems accounted for? If pack lines become unavailable due to updates 
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in pack line software and systems this may not be captured in an OEE measurement. However 
it may be captured in an Equipment Effectiveness E or OEEM measurement. E and OEEM 
calculations consider the effect of Planned Maintenance on Equipment Effectiveness. Planned 
maintenance may be used in pharmaceutical sites to mask some of the productivity impacts 
caused by the requirement to update serialisation equipment. Looking at SEMI breakdowns 
on Operations and Non-Scheduled time in Figure 9, how do pharmaceutical companies 
categorise pack line and other serialisation update requirements?  
 
7.12 The OPEX wave in pharma 
 
OEE, OEEM and E measurements are part of the operational excellence framework (OPEX). 
Operation excellence includes Total Productive Maintenance (TPM), Total Quality 
Maintenance (TQM), Just in Time (JIT) and Effective Management Systems (EMS).  The term 
operational excellence was first discussed by Hayes and Wheelwright in 1984 in their book 
“Restoring our competitive advantage” (Hayes and Wheelwright, 1984). The concepts 
associated with the operational excellence grew out of the methodologies adopted by Toyota 
and other Japanese manufacturers. These concepts were later adopted across a wide range 
of industry sectors. The pharmaceutical industry was a late starter when it came to 
operational excellence. This was evident in the high levels of raw materials and finished 
inventory carried by the pharmaceutical sector compared to other industries (Spector, 2018). 
Other sectors such as automotive, electronics and food embraced operational excellence 
techniques in the 1970’s and ‘80’s, most pharmaceutical companies did not start their 
operational excellence journey until the turn of this century (Friedli et al., 2013). The 
University of St. Gallen in Switzerland has led research into operational excellence in the 
pharmaceutical industry. The university benchmarks the industry in terms of operational 
excellence and OEE. See Figure 11.  
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Figure 11 (St. Gallen University, 2020) 
 
The branded pharmaceutical industry enjoyed a high margin environment until the 
introduction of the Hatch Watchman Act in 1984. This legislation paved the way for generic 
drug manufacturers to compete with branded drug companies once a medicine no longer had 
patent protection (MOSSINGHOFF, 1999). The squeeze on margins by generic manufacturers 
provided pharmaceutical companies with a “burning platform” to initiate improvements 
(Schonberger, 2007).  By the start of the 21st century drug companies were starting to feel the 
pressure imposed on the industry by generic medicines. Pharmaceutical companies found 
that their margins started to quickly erode once drugs came off patent. To compete in markets 
not protected by patents, manufacturers needed to adopt lean manufacturing techniques 
(Bellm, 2015).  
The imposition of manufacturing licenses by regulators was often cited as a reason for 
pharmaceutical manufacturers not trying to improve their processes. Processes were seen as 
being frozen and not open to improvement (Friedli et al., 2013). In the mid 2000’s a series of 
leading pharma companies started to adopt operational excellence programs. Examples 
include Genentech (Griffith et al., 2010), Abbott pharmaceuticals (Starke and Kumor, 2013) 
and Pfizer (Werani et al., 2010). Following decades focusing on quality control and 
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stabilisation programs for the control of manufacturing processes, pharma companies now 
moved to a new phase of trying to systematically improve their organizations and processes.   
The adoption of operational excellence techniques by the pharmaceutical industry since the 
2000’s led to substantial improvement in OEE and other key performance. Figure 17 from the 
St. Gallen benchmarking report outlines the improvements in OEE by the pharmaceutical 
company participants between 2006 and 2012. The report cites a 53% gain in OEE 
performance. Compared to other industries however, the pharmaceutical sector still had a 
long way to go. Figure 18 compares the OEE ratings in the food industry to that of the 
pharmaceutical industry. In 2007 the average OEE in a best in class of food processing 
operation was 24% ahead of the average OEE in a best in class pharmaceutical company.  Irish 
pharmaceutical companies were in the vanguard of the Opex revolution. In a 2015 analysis of 










Part of the reason that pharmaceutical companies struggle with OEE compared to other 
industry sectors is due to batch changeover times. Regulations oblige companies to fully clear 
down packing lines between batches (European Commission, 2017b). Information regarding 
batch number, expiry date and serialisation information must also be setup on the pack lines 
before manufacture and each step of the process must be checked and double checked 
against standard operating procedures (SOPs).  Best in class pharmaceutical companies 
achieved a four-fold reduction in changeover times compared to the poorest performing sites 
(Pharma Manufacturing, 2007).  Just in time manufacturing, with build-to-order batches 
mean an increase in the frequency of changeovers. More batch changeovers impact 
negatively on line availability and OEE (Casali, 2019). The serialisation setup process can 
contribute directly to these changeover times.   
At the same time pharmaceutical companies were starting to make strides in OEE gains they 
also started to focus on other operational benchmarks such as raw material inventories, 
demand-based manufacturing, and increased stock turns for finished goods.  
 
 




Figure 14  (Rodgers, 2014) 
 
Some of the negative impacts on OEE identified in the literature and previously discussed, 
were exacerbated by this drive toward lean manufacturing and operational excellence. Any 
delay in setting up serialisation information for a batch during batch changeover impacts 
availability. The more batches that go through a pack line then the greater the risk of the 
serialisation label print and check systems causing errors and effecting product quality.   
Negative impacts on OEE need to be balanced against some of the positive effects of 
serialisation implementation. This balance may be influenced by the age of the pack line. Pack 
line equipment generally has a lifecycle of 20 – 25 years (COMMISSION OF THE EUROPEAN 
COMMUNITIES, 2008a). With the onset of serialisation some manufacturers may have opted 
to replace older pack lines with newer equipment. This capex investment in new equipment 
may also have brought better line speeds and faster changeover times. Even without 
replacing older pack lines, the addition of better cameras and printers during a serialisation 
installation may improve line performance. One vendor reported that a manufactured saved 
$100,000 USD per annum by replacing manual inspectors with an automated vision system 
during a serialisation implementation (Pirrera and Jordan, 2014). Another vendor reports that 
a client started to seriously monitor OEE post serialisation. By working closely with operators 
the business was able to eliminate waste and increase OEE by 20% (Butschli, 2017).   
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The pharmaceutical pack line is the epitome of the late stage customisation demanded by 
lean manufacturing. A medicine does not become a medicine until it is correctly labelled and 
serialised for a specific market. Any negative or positive impact on OEE or OEEM will affect a 
manufacturing sites operational efficiency and productivity.  
7.13 Pharmaceutical industry productivity 
 
The St. Gallen studies outline the improvements in equipment efficiency in the 
pharmaceutical industry from 2005 to date. However, during this time period there has been 
no real improvement in pharmaceutical industry productivity. A key indicator of a 
manufacturing company’s progression in lean manufacturing is its inventory turn. That is the 
value of the company’s stock-on-hand compared to its annual sales. Spector reported that 
compared to other manufacturing industries, the pharmaceutical sector made little impact 
on inventory levels in the period 2000 to 2009 (Spector, 2018). Analysis of public company 
data in the period 2007 to date indicates that inventory turn has essentially  flatlined (Discover 
CI, 2020).  McKinsey reports that the cost to produce medicines has not changed across the 
industry as a whole, the generic medicines sector being the only exception. See Figure 19.  
 
Figure 15  (Gyurjyan et al., 2017) 
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This stagnation in the cost of goods as a percentage of total sales across the pharmaceutical 
productivity was also identified by Basu et al during the period 2006 to 2008 (Basu et al., 
2008). Vernon et al identified that the cost of goods in medicines manufacture relates directly 
to the cost of healthcare. Any reduction in the cost of goods is taken as additional margin by 
manufacturers while any increase in the cost of goods is passed on through higher prices 
(Vernon et al., 2007).  If serialisation processes did effect productivity then this may be 
reflected in the cost of goods and the price of healthcare for patients. Serialisation processes 
do not just impact the packaging halls in pharmaceutical companies. A study by GS1 Ireland 
and industry consultants Enterprise System Partners found that serialisation project teams 
included representatives from departments such as packaging, automation, engineering, IT, 
quality, operations, manufacturing, artwork and sales. The Harvard Business Review (HBR) 
terms this type of cross functional activity as “organizational drag”. The HBR reports that 
companies can lose up to 20% of its productive capacity through structures and processes 
that consume personnel’s time (Mankins, 2017). Do serialisation processes cause 
organizational drag in manufacturing organisations?  
 
7.14  Gaps in the literature 
 
Sufficient gaps in the literature were identified to warrant the design of a research method to 
investigate the impacts of serialisation on operational efficiency and productivity in the Irish 
context. The literature provided some base data on the considerations of policymakers and 
industry representatives as to the expected capital and operational cost of serialisation. There 
was little follow up in the literature as to the accuracy of the original expectations outlined in 
policy maker’s impact assessment reports.  No literature was found that discussed a detailed 
impact of serialisation on operational efficiency or productivity. The literature gave some 
indication that efficiency may increase or decrease because of serialisation but there no clear 
outcomes were identified. Very little data was available in the literature that discussed 
serialisation in the Irish context.  The literature did not indicate how serialisation processes 
might have affected pharmaceutical productivity or the cost of goods sold.  
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8. Research Method 
 
This section outlines the research methods used in the study. The reasoning for the method 
is discussed along with its advantages and limitations. This purpose of the research method 
is to determine the the impact of serialisation on the operational efficiency and productivity 
of Irish pharmaceutical manufacturing sites. The research method for the study had three 
objectives: 
(i) To determine if the costs of serialisation outlined by policy makers and industry 
representatives in advance of the implementation of serialisation systems was 
accurate  
 
(ii) To assess the impact of serialisation on operational efficiency by examining 
measures such as OEE and production line availability 
 
(iii) To assess the impact of serialisation on pharmaceutical site productivity by 
examining measures such as Cost of Goods Sold (COGS) and per unit cost. 
Research participants would also be questioned on any correlation between 
serialisation and operational excellence techniques 
 
The methodology chosen for the study was a mixed method incorporating both qualitative 
and quantitative tools. A qualitative research approach was included as it allowed subject to 
be studied in their own surroundings.  (Denzin and Lincoln, 2011).  
Flyberg emphasises that practical knowledge is superior to theoretical knowledge (Flyvbjerg, 
2016). Part of this research is to compare the theoretical projections outlined in the literature 
at the start of serialisation and to compare these predictions with the practical experience of 
manufacturing sites.  
Engineering based research traditionally uses quantitative methodologies. However 
qualitative based research methods can provide unique scientific findings that may not be 
identified by quantitative research alone. In the case of this study, it may be impossible to 
conduct experiments on the impacts of serialisation on high demand pharmaceutical pack 
lines. It is possible to interview members of the pharmaceutical community who did conduct 
such experiments and who did statistical analysis on production lines. The report from the 
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19th International Conference on Design Engineering asserted that qualitative research could 
enable engineers to determine findings that were not obtainable by quantitative methods 
(Lee et al., 2013).  
Szajnfarber and Gralla cite two scenarios when qualitative research should be used in 
engineering studies. The first scenario is when the phenomenon to be studied is new or has 
not been studied. When a new phenomenon is to be investigated there may be a lack of clarity 
on what to measure or a lack of sufficient knowledge to make reasonable modelling 
assumptions. The second scenario when qualitative data may be useful is when it is impossible 
to replicate a model in a laboratory setting or where the context of the experiment is too 
important to ignore (Szajnfarber and Gralla, 2017). In this study it would be virtually 
impossible to get access to a serialisation pack line to determine how serialisation processes 
impact efficiency and productivity. The wider impacts of serialisation infrastructure on IT 
systems, databases, communication interfaces, regulatory departments, design and  supply 
chain would also not be adequately considered. Szajnfarber and Gralla describe how 
qualitative research methods may be used to develop better system understanding and for 
framing hypotheses and correlations.  
Ljungberg and Douglas reported that qualitative research in engineering education was 
under-utilised. They encouraged researchers to use a qualitative approach in research design 












8.1 Semi-structured Interviews using open ended and closed ended questions 
 
Within the framework of qualitative research, the study uses the method of semi structured 
interview to gain insight on the research question. This format was chosen as it allowed the 
researcher to ask open ended questions that could elicit a detailed response from 
interviewees. A study by Hove and Anda cited that semi-structured interviews were 
increasingly used in engineering research (Hove and Anda, 2005). Their study examined semi-
structured interviews with 280 software engineers. The study concluded that in order to be 
successful semi-structured interviews should be: 
(i) carefully planned,  
(ii) that the interviewer should have appropriate subject skills 
(iii) that there is good interaction between interviewer and interviewee 
(iv) and that appropriate tools are used 
 
For the purposes of this study the researcher connected with the interviewees in advance of 
the semi-structured interview process in order to make them aware of the request for 
interview and the general topic for discussion. In the course of employment, the researcher 
developed some understanding of the pharmaceutical packaging sector and of serialisation 
technology. While not a subject matter expert (SME), the researcher has enough subject 
knowledge to adequately conduct an interview with SMEs and to ask appropriate follow up 
questions. The researcher applied software tools such as video conference technology 
(Microsoft Teams) and Excel to interpret the interview data.  
The semi-structured interview process allows the researcher to offer questions and 
statements and for the interviewee to respond to these in the best way they see fit. Cohen et 
al described the semi-structured interview: “There is a clear structure, sequence, focus, but 
the format is open-ended, enabling the respondent to respond in her/his own terms. The 
semi-structured questionnaire sets the agenda but does not presuppose the nature of the 
response” (Cohen et al., 2007) 
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The study uses a questionnaire format with a combination of introductory closed-end 
questions and open-ended questions. This format was chosen because the open-ended 
questions used in the semi structured interview allowed for a deeper analysis of the 
respondents’ experience across the range of research questions. The semi structured 
interview method was suitable for use with a low respondent population. Ireland’s exports of 
fully packaged pharmaceuticals are valued in billions of euros. However, there are less than 
two dozen sites contributing to most of this value.  
The semi structured interview process was also chosen because of the Covid-19 pandemic. 
Face to face interviews were not feasible due to Government mandated travel restrictions as 
well as Covid 19 policies adopted by manufacturers. A focus group-based methodology had 
been considered prior to the pandemic but this was ruled out due to the Covid 19 restrictions 
Sherri Jackson summed up the relative advantages and disadvantages of open ended and 
closed ended questions in research in her book, Research Methods a Modular Approach: 
“Open-ended questions allow for a greater variety of responses from participants but are 
difficult to analyze statistically because the data must be coded or reduced in some manner. 
Closed-ended questions are easy to analyze statistically, but they seriously limit the responses 
that participants can give. Many researchers prefer to use a Likert-type scale because it’s very 
easy to analyze statistically” (Jackson, 2014) 
 
8.2 Sampling Methods & Population 
 
The HPRA list 127 companies in Ireland with pharmaceutical manufacturing licenses (HPRA, 
2020). Of these its estimated that less than 17 sites have machine-based packing lines with 
serialisation activities. This study interviewed respondents from 11 companies. The survey 
sample size represents approximately 65% of the pharmaceutical packing sites in Ireland. 
Questionnaires were sent to the respondents in advance and completed as part of the semi 
structured interview format using video conference technology. Respondents hold positions 
in serialisation, project management and operational excellence.  
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8.3 Instrument & Data Collection 
 
The survey instrument used was a closed and open questionnaire format in a semi-structured 
interview. The process was not self-administered by the respondent but rather the researcher 
worked in conjunction with the respondent to complete the questionnaire during the 
interview process during the video conference session.  
The survey method followed Cohen’s guidance on the layout of questionnaires. The Cohen 
method suggest breaking down the questionnaire into three sections: 
(i)  The first section uses non-threatening factual questions such as position, 
company profile, number of packing lines etc 
(ii) The second section moves to closed questions using multiple choice, scales and 
yes/no type questions. These answers may require a response based on opinion, 
attitudes, or views 
(iii) The final section focuses on open ended questions that seek longer format 
information based on the respondent’s views, opinions, and experience.   
(Cohen et al., 2005) 
The questionnaire started with closed questions establishing the respondent’s background, 
their company profile and the profile of their company’s pack-line and serialisation 
operations. Closed ended questions can be completely quickly by the respondent and are easy 
to code for the researcher. Closed ended question do not differentiate on the basis of 
respondents’ articulateness. This was followed by a series of open questions that encouraged 
the respondents to consider their responses and to draw on past and present experiences. 
Badger et al described open ended questions as not multiple-choice questions with multiple 
correct answers or questions that have a single correct answer. “Rather, open-ended 
questions address the essential concepts, processes, and skills that go beyond the specifics of 
instruction to define a subject area. In general, they require complex thinking and yield 
multiple solutions” (Badger et al., 1992) 
The questionnaire and interview questions were circulated to respondents in advance of the 
semi-structured interview in a PDF format via email. Respondents received the semi-
structured interview questions in advance so that respondents could ensure that the 
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interview met with their company policies and guidelines. The researcher completed the 
questionnaire during the interview process. 
Partly because of Covid 19 restrictions the interview process was conducted using the 
Microsoft Teams platform. The Zoom video conference platform was also provided as an 
option. Part of the advantage of the Microsoft Teams platform is that it has inbuilt video 
recording and transcription available. This allowed a virtual face to face interview while also 
providing a mechanism to record the interview. Braun et al described how the use of the video 
conference format has developed for use in qualitative research (Braun et al., 2017). The use 
of video conferencing software in qualitative research has been facilitated by several factors: 
(a) An improvement in the availability and speed of internet access as well as the 
availability of camera enabled laptops, phones, and tablets 
(b) The ease at which video conferences interviews can be arranged in comparison to face 
to face interview or focus groups when respondents are spread over a large 
geographical area 
(c) An understanding that online methods can complement and potentially improve 
traditional interview and focus group methods 
 
The video conference format allowed the researcher to build a rapport with the respondent. 
Respondents had the option not to use the video feature of the software as desired. The video 
conference instrument allowed the interview to be conducted in the respondents’ own space, 
helping to ensure that the interviewee was comfortable. The video conference format 
provides researchers with the ability to see non-verbal clues from respondents compared to 
a traditional phone call. However compared to a face to face interview many non-verbal 
indicators could be missed (Seitz, 2015). The headshot provided on a video conference call 
only provide part of the non-verbal indicators available (Cater, 2011). Janghorban et al 
concluded that the video conference method, Skype (now Microsoft teams) was suitable as 
an alternative or as a supplementary instrument to interview based qualitative research 
(Janghorban et al., 2014). Studies by Archibald et al described respondents positive 
experience using video conference platforms in qualitative research. Respondents cited the 
convenience, ease of use, security and interactivity of video conference calls. The ability to 
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share screens was also important to respondents in the Archibald et al study (Archibald et al., 
2019).  
Given the Covid-19 restrictions some interviews were conducted with the respondents in 
their homes while others were conducted at their place of work. Sy et al, discussing the use 
of video conferencing technology as qualitative research tool during the Covid-19 point that 
while video conferencing enables research to continue while both researcher and respondent 
have restricted movement that consideration should be given to research design, data 
collection methods and ethics (Sy et al., 2020).  
 
8.4 Code of Ethics 
 
At the start of the interview process it was stated clearly to interviewees that their 
confidentiality was assured and that their anonymity would be preserved. An explanation of 
the steps taken to ensure confidentiality and anonymity during the research process was read 
out to the respondents as part of the questionnaire at the start of the interview.  In order to 
ensure anonymity participants were not asked for their names or the names of their company 
during the interview process. Participants were asked in advance of the questionnaire and 
interview process if any special permissions are required from their employer to participate 
in the research. None of the companies represented in the research will be identified and no 
specific information will be sought. Respondents may be asked to indicate the range or 
category of impact on their operations but not for specific data points.   
A method of pseudonymity is used to protect the identity of the participants and their 
employers. Pseudonyms are used in the preparation of written transcripts from the 
respondents and in any subsequent documents or publications. Pseudonyms will be adopted 
as soon as possible within the transcription and analysis phase. Each participant will be 
assigned a code. The register of codes and names will be held on a written sheet, stored in a 
locked cabinet. Video recordings made during the interview process will be immediately 
deleted following transcription and anonymisation. Any printed copies of the transcription 
will be held in a locked filing cabinet. Soft copies of the transcribed interview will be stored 
electronically using encryption and password protection.  
52 
 
8.5 Data Analysis 
 
The data received through the questionnaire was manually coded using an Excel Spreadsheet. 
Each questionnaire and transcription were assigned a number and the details inputted into 
the spreadsheet. A key word analysis was used on the transcription of the open-ended 
questions from the questionnaire. A coding frame was used to identify and tabulate key words 
and recurring themes. Excel was used to generate graphs and tables to represent the data. 





















9.1  Introduction 
 
The researcher interviewed 13 representatives from 11 pharmaceutical companies. The 
participating companies provided a strong representative sample of the Irish pharmaceutical 
packing industry. The companies interviewed make up approximately 65% of the major 
pharmaceutical packing sites in Ireland. The majority of the sites interviewed were large 
volume sites with 49% of respondents producing over 20 million pharmaceutical packages per 
annum. 30% of respondents produced over 50 million packs per annum.  
The respondents to the survey all had direct experience with serialisation implementation 
and operations. Respondents held positions in operations, engineering, opex and information 
technology. 85% of interviewees had over 10 years’ experience in the pharmaceutical industry 
and 60% had greater than 15 years’ experience.  Participants held positions ranging from 
global serialisation leaders, local serialisation subject matter experts (SME), director of 
engineering, capex project managers and opex experts. Each position and discipline brought 
its own perspective on the research questions. 
In total the survey covered the operation of 114 packing lines. Of these pack-lines, two thirds 
(66%) were serialised and 39% had aggregation capabilities. Of the 76 serialised lines 
discussed in the survey 45 had aggregation capabilities meaning that 59% of the pack lines  
discussed had track and trace capabilities. For the purposes of survey and interview the 
researcher grouped serialisation and aggregation activities together as one process is an 
extension of the other.  
The findings were broken into the following themes: 
(i) Serialisation and operational efficiency 
(ii) Serialisation and production line availability 




9.2 Serialisation and operational efficiency 
 
Of the 11 companies and 13 industry professionals that took part in the survey and interview 
process, all expressed an opinion that the OEE of pack lines was adversely affected by 
serialisation.  Except for one site, all the respondents indicated that OEE was measured in 
their packing facilities. Only one site had a fully automated OEE system across all its pack lines. 
Even at this site there was a necessity to produce manual reports from the automated data 
capture system. Two other sites had one or two pack machines that were capable of 
measuring OEE automatically, but for the most part these sites still operated on manual OEE 
data gathering and calculations. 89% of the sites surveyed conducted manual OEE data 
gathering and calculations. Sites did have plans to move to automatic OEE capture with OSI 
PI, OEE Systems and Werum mentioned as potential partners for automated OEE data 
capture.  
Most pack-lines discussed in the survey were retrofitted. One participant described 
serialisation as trying to modify a car while it is still in motion. In 4 of the companies surveyed 
100% of their pack lines were retrofitted. In comparison just one company purchased entirely 
new  pack-line equipment for the serialisation project. Most companies needed to interweave 
the deployment of serialisation processes into existing pack-line operations without 
disrupting production. The process of retrofitting pack lines for serialisation means a loss of 
line availability. A line that is unavailable for production due to a serialisation upgrade will 
have a negative impact on site productivity. New pack lines with inbuilt serialisation systems 
can be tested and validated at the OEM’s premises without affecting existing operations. The 
survey revealed that the average age of a pack line among participating companies was 11 
years. The literature review had mentioned a lifespan of 20 years for a pharmaceutical pack 
line. This means that over the next 10 years companies will need to replace pack machines 




Participants  were shown the graph in Figure 11 on the predicted impact of serialisation on 
operational efficiency. Interviewees discussed their experience compared to the experience 
outlined in the ISPE article.  
  Participating company response 
Months Article % 1 2 3 4 5 6 7 8 9 10 11 
1-3 5 -10 n/a n/a 15 50 15 11 n/a n/a n/a 20 30 
3-12 3-8 n/a n/a 12 15 5 5 n/a n/a n/a 7 20 
>12 1-5 n/a n/a 10 2 2 3 n/a n/a n/a 2 0 
Table 2 OEE losses 
Table 1 shows that that  half of the participating companies could not describe a loss of OEE 
post serialisation. Even though most companies (90%) indicate that they record OEE only 50% 
could indicate if serialisation had any impact on efficiency. It may have been that a 
serialisation SME may not have OEE data readily available. However, in at least two responses, 
an operational  excellence respondent was not able to provide pre and post serialisation data 
even though the company manually recorded OEE data. This result may indicate that 
companies had not considered the impact on OEE sufficiently in advance of the serialisation 
project.  
   Company No.  
Month ISPE Article % 3 4 5 6 9 10 11 
1-3 5 -10 15 50 15 11 0 20 30 
3-12 3-8 12 15 5 5 0 7 20 
>12 1-5 10 2 2 3 0 2 0 
Table 3 Companies indicating a post serialisation loss in OEE 
The average OEE loss reported by the companies surveyed was 2.71%. Two companies 
reported having no loss in OEE despite reporting additional time spent on line changeovers. 
Removing these two companies from the data yields an average negative OEE impact of 3.8%. 
In those companies that did indicate post serialisation OEE measurements, one company did 
cite a significant loss to OEE. Company # 4 in Table 2 is a high-volume manufacturer. The 
company reported a 15% loss to OEE in the 90-day period post serialisation. The ISPE report 
had predicted a maximum loss of just 10%. In the period up to 12 months post serialisation 
the ISPE report predicted a maximum loss of 5% while this manufacture experienced a loss of 
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12%. The ISPE article predicts a maximum loss of just 5% after 12 months. This manufacturer 
continued to see a loss of 10% compared to its pre-serialisation situation. In the period up to 
12 months post serialisation the ISPE article had underestimated the losses for this 
manufacturer by 50%. One year post serialisation the ISPE article had underestimated the 
losses for this manufacturer by 100%. Perhaps the data from this manufacturer was 
inadequate? In the interview with this manufacturer it was outlined how the company had 
taken great care to formalise its OEE measurements in the run up to the serialisation project. 
The company established a ‘level playing field” across all its manufacturing sites to properly 
define and measure the potential impact of OEE. The company had a global team available to 
monitor the OEE impact of serialisation. Of all the companies interviewed, the company with 
the highest reported losses seemed to have the most robust, benchmarked, OEE 
measurement process. Based on the interview with the participant the researcher would have 
a high degree of confidence in the OEE losses indicated by this company.  
Company # 4 reported that after 12 months its OEE figures were in line with the ISPE article 
with an OEE loss of just 2%. However, in the 12 month period following the implementation 
of serialisation the OEE losses reported by the company were significantly higher than those 
outlined in the ISPE article. Company #4  initial losses 90 days post serialisation were 5 x times 
that indicated by the ISPE article. In the 3-month-to-12-month period post serialisation losses 
were double that expected from the ISPE article. Company #5 and #6 were broadly in line 
with the ISPE article expectations.  
Company #1 did not have post serialisation OEE results. However, in interview the company 
did  report that they experience reworks due to serialisation errors about 15 times per year. 
Reworks involving serialised products are very complex to process. The participant described 
how each rework takes 4 x staff and 3 x days labour to process. In terms of availability this 
equates to 45 days lost production on one pack line, per annum or a 18.75% loss in availability 
if the site operated on a single shift per day. Across the site in question the rework issue 
equates to a 2% loss of availability across all pack lines. This does not consider the time taken 
for line setup challenges, additional documentation to complete batches or other errors 
associated with serialisation. One contributor described the serialisation process as adding 
between 10 – 15 minutes to each batch setup. However, another  serialisation manager at 
the site described serialisation as currently having zero impact on OEE.   
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The same company described testing of the data matrix code scan quality every 15 minutes. 
If a single unit fails, then all product going back to the last positive test must be removed for 
testing. At a line speed of 100 parts per minute, 1500 products may need to be tested due to 
a print error on a single package.   
Company # 2, which does not measure OEE as key performance indicator (KPI), described a 
product recall situation because an additional set of characters included in the 2D matrix code 
did not scan at the distribution centre. This meant that the entire batch need to be reworked.  
Even if this type of quality errors is infrequent the increased risk posed by the serialisation 
processes should not be ignored.   
Company # 5 described the use of challenge materials to check cameras on the serialisation 
system. These challenge tests and associated paperwork increase the setup time for each 
batch.  
Company #6 reported that Initially, post serialisation implementation, setup times for 
serialisation increased to 45 minutes. Over time the serialisation setup time has reduced to 
20 minutes per batch. The company described doing approximately 1,000 serialised batches 
per year. This equates to 333 hours per annum for serialisation batch setup. Across 6 x 
serialised lines on one shift this equates to a 2.89% OEE loss. This equates to the company 
reported loss of 3% loss in OEE due to serialisation. However, in addition company #6 also 
described a loss of line speed due to serialisation of between 5 – 10%.  
Company # 10 reported that OEE was impacted by 2% post serialisation. The company 
described how line speeds needed to be reduced by 10% to 15% to ensure that print quality 
was acceptable for certain products. This was dependent on the quality of packaging 
materials. Poorer quality packaging would require a reduction in line speed for inkjet printers 
to produce acceptable 2D matrix codes. Machine vibrations could impact the ability of laser 
printers to print correctly. The quality of glue used in tamper evident seals could cause divots 
and bumps on cartons that would cause print issues. The participant from the company 
described how serialisation was less forgiving on printers and vision systems than in the 
period prior to serialisation. The company also described how In Process Control (IPC) checks 
would identify print errors in the 2D matrix codes. Poor print quality would need to be traced 
back to the last good unit printed. In the 30 minute period between IPC checks 6,000 units 
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could be removed from the line for visual inspection or rework. The company also described 
how setup time for each batch increased by 50% due to serialisation processes. For simple 
batch changeovers, changeover time went from 30 to 45 minutes. When container sizes were 
changed the change-over time went from 2.5 hours to 3 hours due to line challenges following 
line adjustments.  
Company # 11 also reported that serialisation processes increased changeover times by 15 to 
20 minutes to allow for line vision challenge tests and documentation.   
Company # 9 reported that serialisation processes did not impact their OEE. However, the 
company did report that their line speeds were optimised for packaging quality which may 
indicated that line speeds were reduced to cope with the demands of effectively printing 2D 
codes. The company also reported additional batch setup time but no impact on OEE. 
Participants cited several factors for improvements in OEE post serialisation. Operator 
training, the development of subject matter experts and knowledge sharing between pack-
line teams all contributed to better pack-line effectiveness. Better operating procedures and 
software improvements from vendors were also cited as routes to efficiency gains.  One high 
volume site that experienced a high degree of OEE loss went so far as to develop its own ink 
formulation for the inkjet printers used in serialisation to improve print quality on the data 











9.3 Serialisation and line availability 
 
Serialisation should not be as a once-off project. Since the introduction of serialisation by the 
U.S. and European regulatory authorities there has been a series of upgrades and new 
regulatory milestones. Besides FDA ana EMA regulations, serialisation hurdles have been 
provided by Turkey, China, Brazil, Saudi Arabia and Russia. Each new market may have its own 
requirements and will necessitate serialisation vendors to provide software patches and 
upgrades. Among the customers surveyed the first serialisation project started in 2011. One 
company did not start its serialisation project until 2018, just ahead of the European falsified 
medicines directive deadline in February 2019.  
 
Figure 16 Start of serialisation projects 
Serialisation SME’s described how they are often challenged by team members in  operations, 
scheduling and opex about the impact of serialisation and aggregation on line availability. The 
survey asked participants how often serialisation systems needed to be updated. 55% of the 
companies’ surveyed have upgraded their lines for serialisation at least once per year. 85% of 
participants upgrade lines at least once every eighteen months. In interview participants 
described how line upgrades take between 2 weeks and six weeks to implement. Major 
upgrades such as the addition of aggregation capabilities can take between 3 to six months 
to install. When lines come out of production to undergo these upgrades the loss of 
availability is not accounted for in OEE calculations. The loss of availability is tagged as planned 
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Effectiveness factor may be used to account this loss of availability. Only one of the companies 
surveyed used OEEM or Equipment Effectiveness as a measure of line availability. However, 
three sites did describe other measures used to capture the loss of line availability. These 
measures included calculations for line utilisation, max capacity Vs actual production and site 
potential capacity calculations. Company #10 had calculated that taking one pack-line off the 
production schedule for one week equated to a loss of 570,000 units or a 1.14% loss in annual 
production capacity. The same company reported that this type of line upgrade was required 
once per year.  Figure  17 below records the frequency at which participants make pack lines 
unavailable so that upgrade work can be carried out. 
 
Figure 17 Frequency of line upgrade work 
 
Companies # 1, #6 and #9 reported that line upgrade work resulted in additional evening and 
weekend shifts, creating additional cost to the business. 55% of the companies surveyed 
reported that upgrade work takes approximately two weeks. Most of this time is taken up 
with qualification, validation and change control processes. The addition of aggregation 
functionality is a major upgrade program. Company #1 reported that an aggregation project 





9.3 Serialisation and productivity 
 
Four companies in the survey were able to identify a cost per pack associated with 
serialisation. Cost to serialise a pack ranged from 2.5 cents to 6 cents. The average cost was 
4.1 cents. This cost aligns with the 5 cent per pack outlined in the 2008 European Commission 
report (COMMISSION OF THE EUROPEAN COMMUNITIES, 2008b). The Commission report 
uses a cost of 2 cent per pack after 5 years presumably because of depreciation.  
Based on the volumes of production provided in the survey and interview the companies 
which identified their cost per pack to serialise would have the following annual costs: 
Company Cost per pack Est. annual units Cost 
Company # 3 2.5c 5m €125K 
Company # 5 6c 60m €3.6m 
Company # 7 5c 90m €4.5m 
Company # 11 3c 50m €1.5m 
Table 4 Serialisation cost per pack 
The scale of cost experienced by high volume manufacturers  can be seen in Table 3.  
Participants were asked if the additional costs associated with serialisation were reflected in 
the cost of goods or unit cost per item produced. Four of the companies surveyed were able 
to provide a percentage impact on unit costs. 
Company % increase in COGS/Unit Cost 
Company #10 1.9% 
Company #5 0.5% 
Company #3 2.5% 
Company #7 5.4% 
Table 5 Impact on cost of goods/unit cost 
The average increase in cost of goods reported was 2.6%. In the case of company #7 and 
company #10 the increase in cost of goods is conservative. The figure was calculated using 
the depreciation cost associated with serialisation equipment only. It does not consider the 
labour costs associated with running a serialisation line. The use of depreciation cost is 
particularly useful when examining the impact of serialisation. Four of the companies 
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surveyed still consider serialisation process to be in the project phase. Even though serialised 
lines are in operation, ongoing upgrade work means that project resources are still applied. 
The costs associated with serialisation can be difficult to calculate as budgets are still split 
between capital projects, operations, local and corporate company structures. Depreciation 
however cuts across both capital and operational budgets. By using depreciation costs the 
researcher was able to calculate a serialisation depreciation  factor for productivity 




𝑈𝑛𝑖𝑡 𝑐𝑜𝑠𝑡 𝑥 𝑢𝑛𝑖𝑡𝑠 𝑝𝑟𝑜𝑑𝑢𝑐𝑒𝑑 𝑝𝑒𝑟 𝑎𝑛𝑛𝑢𝑚
 
The serialisation depreciation factor provides a simple method to capture part of the costs of 
serialisation as projects move from initial installation through to business as usual (BAU). 
Survey participants were shown the prediction from the 2008 European Commission report 
that suggested that the cost of serialisation per pack line at €150,000 per line. Respondents 
indicated that the cost to serialise a pack line ranged from €250,000 to €900,000 depending 
on the functionality required. The average cost to serialise a pack line was estimated at 
€600,000, which four-fold what the E.C. impact report suggested. 
These high capital costs have a direct impact on the future operations of the pharmaceutical 
sites. The capital outlay on serialisation equipment creates a depreciation weight on 
operational budgets. One participant described serialisation as having no benefit to the 
business and created a cost that was difficult to pass on to contracted customers. Another 
respondent described how the weight of depreciation on the budget was restricting the site’s 
ability to invest in other equipment and that the company was unable to pass on the 
additional costs to their corporation.  
Participants were also asked about the ongoing operational costs associated with 
serialisation. Additional operational costs might include labour costs, data costs, regulatory 
registration costs and code costs for markets such as China and Russia. While 91% of the 
companies surveyed cited that serialisation did require additional labour costs, only 55% were 
able to calculate what the additional labour cost was for their organization. The 2014 Pew 
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Healthcare report predicted an additional labour costs to manufacturers of €242,000 per 
annum. Respondents averaged the additional cost of labour at €88,000 per pack line.  
Accepting a conservative calculation of an average increase in the cost of goods of 2.7% we 
can assess the impact across the Irish pharmaceutical market. The Central Statistics office 
(CSO) in Ireland reported that in 2019 Ireland exported €15.9bn of packaged pharmaceutical 
goods (Commodity Number 3004). Some of these packaged pharmaceuticals will be filled into 
their primary packaging containers for export to packing sites outside of Ireland. The CSO does 
not distinguish between pharmaceutical is primary packaging or fully finished secondary 
packaged good. If we calculate that one third of exports are in their secondary packaging 
format and that COGs makes up 25% of sale price (Gyurjyan et al., 2017) then a 2.7% increase 
in the unit cost is valued at €36m per annum. If intra-company pricing is used for the 
calculation, then the annual cost is expected to be €143m per annum.  
 
All the companies surveyed, except for one had an in-house lean manufacturing or 
operational excellence team. When asked if operational excellence programs had pushed 
their companies to produce more just-in-time orders, to reduce batch sizes and decrease 
inventory positions, 55% of respondents said that they now processed more batches annually. 
However, during interviews with participants it was clear that many companies were trying 
to move away from the pure Just in Time (JIT) approach. Nine of the eleven companies (81%) 
reported that they were actively increasing batch sizes to achieve productivity gains. The 
philosophy behind smaller batch sizes comes from both the internal demands of operational 
excellence programs to minimise inventories and from market driven demand. One 
participant described how sales and marketing team members needed to understand that 
pack line machines were built for high volume production rather than small batch runs.  
When asked if serialisation had exacerbated the inefficiencies associated with small batches 
only 55% of respondents agreed. However, among large volume manufacturers 90% of 
respondents agreed that serialisation processes had put extra strain on changeover times and 
efficiencies. Company #10 described a batch that might take 10 minutes to run but one hour 
to setup. Three companies described how they had decoupled upstream filling from the pack 




The aim of this research was to determine the impact of serialisation on operational efficiency 
and productivity on Irish pharmaceutical sites. The research had three objectives, firstly to to 
test the assumptions made by industry bodies and policy makes in advance of the 
implementation of serialisation. Secondly, to assess the impact of serialisation on operational 
efficiency and finally to determine the impact of serialisation on site productivity,  
The research found that serialisation did have a negative impact on operational efficiency in 
Irish pharmaceutical sites. There was some postulation in the literature prior to the 
implementation of the Drug Supply Chain Security Act (DSCSA) and the European Falsified 
Medicines Directive (FMD) that serialisation could provide improvements in operational 
efficiency. There was an argument that new equipment and interconnected systems could 
improve operational effectiveness. These efficiency improvements have not manifested 
themselves in the Irish context.  
Operational Equipment Effectiveness (OEE) is a key measurement of efficiency. The research 
found that post serialisation efficiencies have dropped on the Irish manufacturing sites 
surveyed in this research by an average of 2.71%. Adjusting for two companies that reported 
zero negative impact on OEE despite having reported additional time required for batch 
changeovers, the research revealed a 3.8% loss in OEE.  
The research points to a limited implementation of OEE systems in Irish pharmaceutical 
manufacturing sites. While 89% of the sites surveyed gathered OEE data it seemed there was 
a lack of benchmarking of OEE data prior to serialisation. Many sites only recorded data on a 
limited number of pack machines. Some sites pointed to delays in machine setup due to 
serialisation but also reported a zero loss of OEE.  
Line availability is an important component of OEE calculations. Continuing changes to 
regulations and the adoption of serialisation in new markets mean that that pack lines are 
often removed from production duties for upgrade work. This loss of availability is not 
captured in the OEE calculation as the machine loss is recorded as planned downtime. 55% of 
survey participants recorded carrying out upgrade work every 18 months or less. Typical 
downtime was 2 weeks. Major upgrade work such as the addition of aggregation functionality 
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might mean the loss of a line for between three and six months. The loss of availability from 
these lines targeted for upgrade means additional labour costs for the business. Other 
production lines need to work longer hours to take up the slack. Only one third (36%) of the 
companies surveyed used measurements to capture this significant loss of line availability.  
Because of the ongoing upgrades to serialisation equipment there is an overlap between 
capital projects and operations in Irish pharmaceutical sites. It is difficult to track the costs 
associated between capital projects and operations. The Serialisation depreciation factor SDf 
provides a simple calculation to assess the impact of serialisation on unit cost. Capital costs 
accrued in the project phase of serialisation are reflected in operational costs through 
depreciation line items.  
The impact of serialisation on unit cost and cost of goods is not insignificant. Using the SDf 
calculation the researcher could calculate the impact of serialisation on unit cost as an 
increase of 2.7%. Based on Irish Central Statistics office figures this represents an increase in 
the cost of packaged pharmaceutical goods exported from Ireland of between €36m - €143m 
per annum (depending on whether distribution or intra-company pricing is used) Some 
participants in the survey complained that their businesses were expected to absorb these 
additional costs. Research would indicate that these additional costs are ultimately passed 
onto patients and payer organizations (Suresh and Basu, 2008). Some companies had 
calculated a cost per pack for serialisation. The average cost per pack was 4.1 cents. For large 
volume sites the annual cost of serialisation is significant running to millions of euro per 
annum.  
The research also identified a trend in Irish based pharmaceutical sites away from just-in-time 
manufacturing. 81% of participating companies reported that they were actively seeking to 
increase batch sizes and decrease their product range to claw back operational efficiency. 
While no correlation could be made that serialisation exacerbated the impact of smaller 
batches on pack line efficiency it was clear that the companies surveyed were intent to 
increase batch sizes to achieve better efficiency.  
The research also looked back on the assessments of policy makers and industry bodies in 
advance of the track and trace regulations. From the literature it was clear that little if any 
consideration was given to the potential impact of serialisation on efficiency and productivity. 
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Estimations by policy makers on the cost on the costs associated with serialisation were also 
inadequate. This research indicated that policy makers underestimated the cost of 
serialisation projects by a factor of four. A 2008 European Commission Assessment report had 
predicted an average cost of serialisation per pack of 5 cents. This figure aligned with the 
experience of the survey participants which reports a 4.1 cents average cost per pack for 
serialisation. The average cost per pack is a telling indicator. High volume sites report an 
annual cost of serialisation of up to €4.5m per annum. 
The 2018 ISPE report used in the survey was found to be reliable in terms of the experiences 
of the sites interviewed.  The overall result postulated in the report aligned with the 
experience of participants in the year after serialisation implementation. However, the impact 
on efficiency immediately after the implementation of serialisation was much more acute in 
the Irish context.  
As a follow up to this study further research could be conducted to narrow down the annual 
cost of serialisation in Irish pharmaceutical sites. This study might require access to financial 
managers to get access to data on depreciation and operational costs. A study on the 
fundamental question of the effectiveness of the falsified medicines directive might also be 
worthwhile. Did all the effort to serialise medicines meet its objective to protect drug supply 
chains, particularly in developing countries? Finally, a study on the impact of Brexit on 
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12.2 Consolidated Report from survey and interviews 
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